Abstract
In 22 histologic cases of subcutaneous panniculitis-like lymphoma, we studied the clinicopathologic differences between CD56- and CD56+ cases (11 each). CD56- cases had skin ulcers (1 [9%]); tumor invasion in the superficial dermis (1 [9%]); erythrophagocytosis (10 [91%]); and medium-sized (11 [100%]), CD8+ (10 [91%]), T-cell receptor (TcR)βF1 + (10 [91%]), and CD95 (Fas)- tumor cells. CD56+ cases had skin ulcers (9 [82%]); tumor invasion in the superficial dermis (8 [73%]); erythrophagocytosis (1 [9%]); and pleomorphic large (10 [91%]), CD8+ (2/10 [20%]), TcRβF1 + (3/10 [30%]), and CD95 (Fas) + (7/10 [70%]) tumor cells. These 7 factors were significantly different between groups (P < .01) Median survival rates were 96 and 12 months for the CD56- and CD56+ groups, respectively. Age younger than 40 years, no skin ulcers, no tumor invasion in the superficial dermis, and CD8+, TcRβF1 +, CD95 (Fas)-, and CD56- tumor cells were significantly better prognostic factors (P < .01). The CD56- and CD56+ groups showed different tumor cell characteristics, clinicopathologic findings, and prognosis. In the CD56+ group, 1 was γ/δ T-cell phenotype, 3 were α/β T-cell, and 6 were TcRβF1- and γ/δ- NK/T-cell, and 3 NK/T-cell cases had nuclear signals of Epstein-Barr virus-encoded RNA. Cases of CD56+ T- and NK/T-cell lymphoma had similar clinicopathologic findings and prognosis.
| Original language | English |
|---|---|
| Pages (from-to) | 408-416 |
| Number of pages | 9 |
| Journal | American Journal of Clinical Pathology |
| Volume | 121 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jan 1 2004 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pathology and Forensic Medicine
Cite this
Clinicopathologic Analysis of 22 Cases of Subcutaneous Panniculitis-Like CD56- or CD56+ Lymphoma and Review of 44 Other Reported Cases. / Takeshita, Morishige; Imayama, Shuhei; Oshiro, Yumi; Kurihara, Kenji; Okamoto, Sumika; Matsuki, Yasumasa; Nakashima, Yutaka; Okamura, Takashi; Shiratsuchi, Motoaki; Hayashi, Toru; Kikuchi, Masahiro.
In: American Journal of Clinical Pathology, Vol. 121, No. 3, 01.01.2004, p. 408-416.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinicopathologic Analysis of 22 Cases of Subcutaneous Panniculitis-Like CD56- or CD56+ Lymphoma and Review of 44 Other Reported Cases
AU - Takeshita, Morishige
AU - Imayama, Shuhei
AU - Oshiro, Yumi
AU - Kurihara, Kenji
AU - Okamoto, Sumika
AU - Matsuki, Yasumasa
AU - Nakashima, Yutaka
AU - Okamura, Takashi
AU - Shiratsuchi, Motoaki
AU - Hayashi, Toru
AU - Kikuchi, Masahiro
PY - 2004/1/1
Y1 - 2004/1/1
N2 - In 22 histologic cases of subcutaneous panniculitis-like lymphoma, we studied the clinicopathologic differences between CD56- and CD56+ cases (11 each). CD56- cases had skin ulcers (1 [9%]); tumor invasion in the superficial dermis (1 [9%]); erythrophagocytosis (10 [91%]); and medium-sized (11 [100%]), CD8+ (10 [91%]), T-cell receptor (TcR)βF1 + (10 [91%]), and CD95 (Fas)- tumor cells. CD56+ cases had skin ulcers (9 [82%]); tumor invasion in the superficial dermis (8 [73%]); erythrophagocytosis (1 [9%]); and pleomorphic large (10 [91%]), CD8+ (2/10 [20%]), TcRβF1 + (3/10 [30%]), and CD95 (Fas) + (7/10 [70%]) tumor cells. These 7 factors were significantly different between groups (P < .01) Median survival rates were 96 and 12 months for the CD56- and CD56+ groups, respectively. Age younger than 40 years, no skin ulcers, no tumor invasion in the superficial dermis, and CD8+, TcRβF1 +, CD95 (Fas)-, and CD56- tumor cells were significantly better prognostic factors (P < .01). The CD56- and CD56+ groups showed different tumor cell characteristics, clinicopathologic findings, and prognosis. In the CD56+ group, 1 was γ/δ T-cell phenotype, 3 were α/β T-cell, and 6 were TcRβF1- and γ/δ- NK/T-cell, and 3 NK/T-cell cases had nuclear signals of Epstein-Barr virus-encoded RNA. Cases of CD56+ T- and NK/T-cell lymphoma had similar clinicopathologic findings and prognosis.
AB - In 22 histologic cases of subcutaneous panniculitis-like lymphoma, we studied the clinicopathologic differences between CD56- and CD56+ cases (11 each). CD56- cases had skin ulcers (1 [9%]); tumor invasion in the superficial dermis (1 [9%]); erythrophagocytosis (10 [91%]); and medium-sized (11 [100%]), CD8+ (10 [91%]), T-cell receptor (TcR)βF1 + (10 [91%]), and CD95 (Fas)- tumor cells. CD56+ cases had skin ulcers (9 [82%]); tumor invasion in the superficial dermis (8 [73%]); erythrophagocytosis (1 [9%]); and pleomorphic large (10 [91%]), CD8+ (2/10 [20%]), TcRβF1 + (3/10 [30%]), and CD95 (Fas) + (7/10 [70%]) tumor cells. These 7 factors were significantly different between groups (P < .01) Median survival rates were 96 and 12 months for the CD56- and CD56+ groups, respectively. Age younger than 40 years, no skin ulcers, no tumor invasion in the superficial dermis, and CD8+, TcRβF1 +, CD95 (Fas)-, and CD56- tumor cells were significantly better prognostic factors (P < .01). The CD56- and CD56+ groups showed different tumor cell characteristics, clinicopathologic findings, and prognosis. In the CD56+ group, 1 was γ/δ T-cell phenotype, 3 were α/β T-cell, and 6 were TcRβF1- and γ/δ- NK/T-cell, and 3 NK/T-cell cases had nuclear signals of Epstein-Barr virus-encoded RNA. Cases of CD56+ T- and NK/T-cell lymphoma had similar clinicopathologic findings and prognosis.
UR - http://www.scopus.com/inward/record.url?scp=10744231158&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10744231158&partnerID=8YFLogxK
U2 - 10.1309/TYRGT196N2APLLR9
DO - 10.1309/TYRGT196N2APLLR9
M3 - Article
VL - 121
SP - 408
EP - 416
JO - American Journal of Clinical Pathology
JF - American Journal of Clinical Pathology
SN - 0002-9173
IS - 3
ER -